Purpose: to investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients with diabetic macular edema (dME) refractory to ranibizumab or bevacizumab.
D
iabetic macular edema (dME) is an important cause of visual impairment in diabetic patients.
1 traditionally, dME has been managed with macular laser therapy with limited effect.
2 Elevated intraocular levels of vascular endothelial growth factor (VEgF) have been shown to promote retinal vascular permeability, which leads to macular edema in diabetic patients. 3 intravitreal injection of anti-VEgF agents has demonstrated efficacy in lowering intraocular levels of VEgF and reducing macular edema in diabetic eyes, including with drugs such as ranibizumab, 4-6 bevacizuamb, 7 pegaptanib, 8 and aflibercept. 9, 10 Bevacizuamb (avastin, genentech inc, south san Francisco, california) is a full-length recombinant humanized monoclonal antibody directed against VEgF-a. intravitreal bevacizumab was found to be more effective in reducing macular thickness and improving visual acuity than macular laser therapy for dME in a previous randomized study conducted over a 2-year period. 7 ranibizumab (lucentis, genentech, inc, south san Francisco, california, and novartis Pharma ag, Basel, switzerland) is an antibody fragment with a high binding affinity toward all forms of VEgF-a. ranibizumab intravitreal treatment for dME has been shown to be more beneficial than macular laser or sham injections in large-scale randomized studies with long-term follow-up. [4] [5] [6] However, patients with dME may develop resistance to intravitreal ranibizumab and bevacizumab treatment, either at the first injection or after several administrations.
11-20 intravitreal injections of corticosteroids, including fluocinolone acetonide implant (iluvien), 11, 12 dexamethasone implant (ozurdex), 13, 14 and triamcinolone acetonide, 15 were reported to be effective in dME cases refractory to bevacizumab or ranibizumab. aflibercept (Eylea, regeneron Pharmaceuticals, inc, and Bayer Pharma ag, Berlin, germany) is a decoy receptor fusion protein composed of the second domain of human VEgF receptor 1 and the third domain of VEgF receptor 2, which are fused to the Fc domain of human igg1. randomized controlled phase 3 trials have demonstrated the efficacy of intravitreal aflibercept 2 mg over macular grid laser in patients with center-involving dME over 2-year followup. 9 recently, 3 studies have reported the utility of intravitreal aflibercept in managing patients with persistent dME despite prior bevacizumab or ranibizumab treatments. [16] [17] [18] However, some cases resistant to previous bevacizumab or ranibizumab injection were found to have poor responses to aflibercept. the purpose of the present study was to investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients with dME refractory to ranibizumab or bevacizumab. Further, risk factors for poor response to aflibercept treatment were evaluated in diabetic patients. aged 18 years or older with a history of diabetes mellitus, evidence of clinically significant macular edema as defined by the Early treatment diabetic retinopathy study, 2 and center-involving dME. center-involving dME was defined as central foveal thickness (CFT) in the central 1-mm area of more than 300 μm measured by spectral-domain optical coherence tomography (sdoct; rtVue, optovue, san Francisco, california) with macular pathologies, including cystoid changes, diffuse thickening, and submacular fluid, using 6 radial line scans through the fovea. From september 2013 to March 2016, patients were retrospectively recruited by chart review. all patients with center-involving dME received 3 monthly and pro re nata intravitreal injections of bevacizumab or ranibizumab combined with macular grid laser within 1 week of bevacizumab or ranibizumab administration. Bevacizumab and ranibizumab injections were performed for dME treatment rather than for retinal neovascularization in diabetic retinopathy. nonproliferative diabetic retinopathy and proliferative diabetic retinopathy were treated with panretinal laser photocoagulation and/or vitrectomy, and cataract receiving uneventful phacoemulsification and in-the-bag intraocular lens implantation were allowed before or during the period of intravitreal bevacizumab or ranibizumab only if patients had undergone any of the above laser and operations before the 6-month period before aflibercept conversion. We identified participants with dME who developed resistance to bevacizumab or ranibizumab, which was defined as a paradoxical increase in cFt and gain in best-corrected visual acuity (BcVa) of less than 1 line at 1 month after at least 3 months of continuous treatment compared with before bevacizumab or ranibizumab administration. We excluded patients with prior ocular trauma, vitreomacular adhesion or traction, epimacular membrane, tractional retinal detachment, vitreous hemorrhage, other ocular disorders, prior intravitreal or sub-tenon injections of corticosteroids or intravitreal corticosteroid implants, or other previous intraocular surgeries. no patient had a history of thromboembolic events, known coagulation abnormalities or current use of anticoagulative medication other than aspirin, or other major systemic diseases except hypertension. aflibercept was injected more than 4 weeks after prior ranibizumab or bevacizumab therapy. Baseline BcVa using snellen charts [converted to logarithm of the minimum angle of resolution (logMar) for statistical comparison], intraocular pressure via pneumotonometry (ct-80, topcon, tokyo, Japan), fundus examination by indirect ophthalmoscope, and biomicroscopy of the anterior segment were performed in all patients. all participants provided informed consent after full explanation of the risks and benefits of switching to aflibercept treatment. three monthly intravitreal aflibercept 2 mg/0.05 ml injections were administered for the treatment of refractory cases. all procedures were performed at Far Eastern Memorial Hospital by 1 surgeon (J.K.W.). all participants were followed monthly for 3 months with anterior segment and fundus examination, BcVa, cFt, and intraocular pressure measurement. Follow-up sd-oct scans used the baseline scan as a reference. Visual testing was performed in the same room at each visit.
Patient demographics, total cholesterol, serum creatinine, glycosylated hemoglobin, lens status, severity of diabetic retinopathy, resistance to prior bevacizuamb and ranibizumab, prior vitrectomy, BcVa, and cFt at baseline and 1, 2, and 3 months were recorded. Baseline cFt and BcVa were compared with values at 1, 2, and 3 months after intravitreal aflibercept using the Wilcoxon signed-rank test. nonresponders to aflibercept were defined as those having a paradoxical increase in cFt and gain in BcVa of less than 1 line at 1 month after treatment compared with those before aflibercept administration. responders to aflibercept were defined as those with a decrease in cFt compared with baseline data and BcVa gains of at least 1 line. clinical data were compared between aflibercept responders and nonresponders using Fisher exact test for categorical variables and Wilcoxon-Mann-Whitney test for numerical variables. P values less than 0.05 were considered statistically significant. results seventy-two eyes in 72 patients with dME developed resistance to bevacizumab (15 eyes) or ranibizumab (57 eyes) treatment before transitioning to aflibercept injections. among all figure 1. Changes of mean best-corrected visual acuity from baseline to month 3 after intravitreal aflibercept in patients with diabetic macular edema resistant to ranibizumab or bevacizumab. Total patients and subgroups with aflibercept responders and nonresponders were depicted in different curves of visual changes.
figure 2. Changes of mean central foveal thickness from baseline to month 3 after intravitreal aflibercept in patients with diabetic macular edema resistant to ranibizumab or bevacizumab. Total patients and subgroups with aflibercept responders and nonresponders were depicted in different curves of visual changes.
patients, the mean age was 58.6 ± 7.2 years, including 55 males and 17 females. there were 25 pseudophakic and 47 phakic eyes. thirteen eyes had nonproliferative diabetic retinopathy, and 59 eyes with proliferative diabetic retinopathy had been treated by panretinal photocoagulation. among these patients, 17 eyes had received previous vitrectomy, and the other 55 eyes had not. Blood test results demonstrated a mean total cholesterol of 188.4 ± 51.5 mg/dl, mean serum creatinine of 1.86 ± 1.6 mg/dl, and mean glycosylated hemoglobin of 7.7 ± 1.2%. the mean baseline BcVa was 0.61 ± 0.32 logMar. Before aflibercept treatment, patients with dME received a mean number of 7.2 ± 3.4 injections of bevacizumab in 15 eyes over a mean duration of 18 ± 4.9 months. a mean number of 5.7 ± 2.1 ranibizumab injections were administered in the other 57 eyes during a mean period of 16 ± 3.4 months. the mean period of time from the last injection of ranibizumab or bevacizumab to the first injection of aflibercept was 2.2 ± 0.4 months. after 3 monthly intravitreal injections of aflibercept, improvements in BcVa were noted after 1 month only (0.46 ± 0.25 logMar, P = 0.03). no significant difference in BcVa was observed at 2 months (0.47 ± 0.27 logMar, P = 0.06) or 3 months (0.54 ± 0.38 logMar, P = 0.47) compared with baseline BcVa values (Fig. 1) . the mean baseline cFt was 442.7 ± 84.3 μm. After 3 monthly intravitreal injections of aflibercept, no significant differences in cFt were observed at 1 month (403.1 ± 100.3 μm, P = 0.08), 2 months (418.7 ± 114.9 μm, P = 0.37), and 3 months (401.2 ± 155.4 μm, P = 0.27) compared with baseline cFt values (Fig. 2) . injections were well tolerated in all patients. there were no episodes of endophthalmitis, retinal detachment, vitreous hemorrhage, or elevated intraocular pressure. the most common side effects were local hyperemia or subconjunctival hemorrhage at the site of injection. no systemic adverse events, such as thromboembolic events, were noted.
of the 72 eyes, 42 eyes (58.3%) responded to aflibercept injections. Baseline data of aflibercept responders are shown in table 1. the BcVa was 0.65 ± 0.32 logMar before aflibercept treatment. after 3 monthly intravitreal injections of aflibercept, improvements in BcVa were observed at 1 month (0.38 ± 0.15 logMar, P = 0.003), 2 months (0.34 ± 0.16 logMar, P = 0.0007), and 3 months (0.31 ± 0.17 logMar, P = 0.0008; Fig. 1 ). The mean baseline CFT was 438.5 ± 80.1 μm. After 3 monthly intravitreal injections of aflibercept, cFt was found to be significantly reduced at 1 month (353.1 ± 107.9 μm, P = 0.08), 2 months (355.6 ± 46.4 μm, P = 0.01), and 3 months (297.9 ± 19.1 μm, P = 0.0004; Fig. 2) . thirty (41.7%) of the 72 eyes responded poorly to intravitreal aflibercept injections. Baseline data of aflibercept nonresponders are shown in table 1. the mean baseline BcVa was 0.55 ± 0.31 logMar. the mean BcVa at 1 month (0.61 ± 0.30 logMar, P = 0.23) and 2 months (0.68 ± 0.28 logMar, P = 0.07) did not significantly differ from baseline BcVa values after aflibercept injections. Paradoxical deterioration of BcVa was observed at 3 months (0.91 ± 0.38 logMar, P = 0.002) compared with baseline BCVA values (Fig. 1) . The mean baseline CFT was 449.1 ± 90.1 μm. after 3 monthly intravitreal aflibercept injections, the mean cFt was increased at 1 month (481.6 ± 107.8 μm, P = 0.03), 2 months (517.7 ± 120.6 μm, P = 0.03), and 3 months (563.6 ± 135.7 μm, P = 0.01; Fig. 2 ).
no differences in baseline characteristics, including age, sex, glycosylated hemoglobin, serum creatinine, total cholesterol, lens status, grades of diabetic retinopathy, and cFt/BcVa before aflibercept management, were observed between responders and nonresponders (P > 0.05 for all; table 1). there were 17 vitrectomized eyes among the 30 nonresponders (56.7%), a significantly higher proportion than among the 42 responders (0%; P = 0.00001). Best-corrected visual acuity values did not significantly differ at 1 month after aflibercept therapy between aflibercept responders and nonresponders (P = 0.12). aflibercept responders had superior BcVa values at 2 months (P = 0.02) and 3 months (P = 0.003) compared with aflibercept nonresponders. the cFt was significantly thinner in aflibercept responders than in aflibercept nonresponders at 1 month (P = 0.02), 2 months (P = 0.01), and 3 months (P = 0.002; table 1). discussion a proportion of diabetic patients with macular edema may develop resistance to ranibizumab or bevacizumab therapy. some patients do not respond to initial ranibizumab or bevacizumab injections. tachyphylaxis occurs in a proportion of patients, that is, a fair response to ranibizumab or bevacizumab initially before becoming refractory to these drugs after a few injections. recently, 3 studies have reported the efficacy of intravitreal aflibercept in managing patients with persistent dME despite prior bevacizumab or ranibizumab therapies.
16-18 rahimy et al 16 retrospectively reviewed conversion to aflibercept for persistent dME in 50 eyes after prior repeated ranibizumab and/or bevacizumab treatment. a mean of 4.1 aflibercept injections were administered within a mean follow-up duration of 4.6 months. conversion to aflibercept resulted in significant reduction of central macular thickness; however, a trend toward improved visual acuity was observed without statistical significance. More than 1 line of visual loss and unchanged macular thickness were found in 20% of cases switched to intravitreal aflibercept. the authors also reported that pre-switch visual acuity and presence of epiretinal membrane were not related to aflibercept response. Wood et al 17 prospectively recruited 14 diabetic eyes undergoing single aflibercept injection for macular edema refractory to prior ranibizumab and/or bevacizumab therapy. one month after intravitreal aflibercept, 79% (11 of 14 eyes) of patients had reduced macular thickness and significant anatomic improvement with a 23% decrease in average central subfield foveal thickness. However, 21% (3 of 14 eyes) had stable or worsening edema. Visual acuity improved in 3 of the 14 eyes at 1 month after single aflibercept; however, this difference did not reach statistical significance. lim et al 18 conducted a retrospective chart review of 21 eyes with dME unresponsive to ranibizumab and/or bevacizumab and subsequently switched to aflibercept. a median of 3 aflibercept injections were administered within a median follow-up duration of 5 months. conversion to aflibercept resulted in a significant decrease in central foveal thickness and significant visual improvement.
in the present study, 72 eyes with persistent dME resistant to previous ranibizumab or bevacizumab therapy were treated with 3 monthly intravitreal aflibercept injections. compared with pre-switch visual acuity, significant visual gains were observed at 1 month only but not observed at 2 or 3 months after conversion to aflibercept. only a trend toward anatomical improvement was observed at 1 month; however, no significant change was observed at 2 or 3 months after conversion to aflibercept. anatomical and functional outcomes were worse than the results of previous studies.
16-18 this difference may be attributable to a higher nonresponsive rate of aflibercept in the present study (41.7%), with nearly 20% of the patients not responding to aflibercept after switching from other anti-VEgF agents in previous studies. 16, 17 Besides, more severe visual and anatomical deteriorations may have been caused by persistent dME observed at 2 and 3 months compared with 1 month in nonresponders, which may offset the effect of stable improvement in the responders and explain why aflibercept was effective at 1 month after the first injection but not at months 2 or 3 in all patients. significant visual and foveal thickness improvements were detected in the other 58.3% of aflibercept responders. the considerable improvement observed after conversion to aflibercept in responders may be attributable to several factors. First, aflibercept has demonstrated superior antiVEgF activity than bevacizumab and ranibizumab in vitro and in vivo. the binding affinity of VEgF for aflibercept is higher than that for ranibizumab and bevacizumab in cell-based bioassays. 21 aflibercept displays a prolonged VEgF inhibition in comparison with ranibizumab and bevacizumab in retinal pigment epithelium/choroid organ cultures.
22 a head-to-head randomized trial reported aflibercept resulted in better visual gains than ranibizumab and bevacizumab in diabetic patients with worse presenting visual acuity due to macular edema after 1-year follow-up. 10 second, aflibercept is able to downregulate not only VEgF-a but also VEgF-B and placental growth factor, which have synergistic effects on pathologic angiogenesis. 21 Patients with diabetic retinopathy have been shown to have high vitreous levels of placental growth factor. 23 Placental growth factor can facilitate the breakdown of the outer and inner blood-retinal barrier, which may lead to the development of dME.
24,25 third, intravitreal aflibercept avoids tachyphylaxis to prior ranibizumab and bevacizumab after repetitive use of these 2 drugs. the mechanisms underlying the development of tachyphylaxis are thought to be multifactorial, involving humoral responses (eg, systemic immune reaction to anti-VEgF molecules contributing to the formation of neutralizing antibodies), cellular responses (eg, upregulation of VEgF from local macrophages, altered expression of surface receptors, or activation of alternate angiogenic signaling pathways), and/or metabolic responses (eg, alterations in pharmacokinetics with changes in drug absorption, distribution, and metabolism). 26, 27 no differences in age, sex, glycosylated hemoglobin, serum creatinine, total cholesterol, lens status, grades of diabetic retinopathy, pre-switch foveal thickness, and pre-switch visual acuity were observed between responders and nonresponders in the present study. a prior study also reported that pre-switch visual acuity was not associated with aflibercept response. 16 We identified previous vitrectomy as the only risk factor associated with aflibercept nonresponsiveness in the present study. this may be attributable to the rapid clearance of intravitreal aflibercept from the vitreous cavity, limitation of aflibercept exposure to the retina, and insufficient therapeutic levels of aflibercept in vitrectomized eyes. the clearance rates of intravitreally placed medications, such as bevacizumab, triamcinolone acetonide, and ranibizumab, have been shown to be faster after vitrectomy in animal studies. [28] [29] [30] in vitrectomized human eyes with dME, intravitreal bevacizumab has been shown to result in incomplete responses in visual acuity and/or macular thickness after short-term follow-up. [31] [32] [33] therefore, we conclude that vitrectomized eyes may be at greater risk of being refractory to aflibercept in diabetic patients.
thirteen eyes with dME refractory to ranibizumab or bevacizumab did not undergo previous vitrectomy but still responded poorly after conversion to aflibercept. the pathogenesis of resistance to anti-VEgF agents is presumed to involve an elevation in intraocular levels of other cytokines causing dME, even under complete inhibition of VEgF by aflibercept. Elevated aqueous levels of interleukin-6, interleukin-8, interferon-induced protein-10, monocyte chemotactic protein-1, transforming growth factor β, hepatocyte growth factor, serum amyloid A, and VEGF were found in patients with dME.
34,35 intravitreal bevacizumab lowers intraocular amounts of VEgF only. 34,35 intravitreal injections of corticosteroids can inhibit various elevated intraocular cytokines, which are effective in patients with refractory dME. [11] [12] [13] [14] [15] schmit-Eilenberger 12 demonstrated improved BcVa in 11 (73.3%) of 15 eyes with chronic dME unresponsive to VEgF antagonists or corticosteroids that had received intravitreal fluocinolone acetonide implants. totan et al 14 and Zhioua et al 13 reported the efficacy of single dexamethasone intravitreal implantation for patients with dME nonresponsive to previous bevacizumab or ranibizumab from the first to third month after administration. However, the therapeutic efficacy decreases between the third and sixth months after treatment.
13,14 Kim et al 15 reported significant improvements in BcVa and decreases in cFt at 1 month but no improvement at 3 months after single intravitreal triamcinolone acetonide injection in 20 eyes with bevacizumab-resistant dME. However, ocular hypertension and cataract were rarely observed after intraocular injection of corticosteroids.
11-15 in the present study, diabetic patients with refractory dME did not respond to aflibercept and corticosteroid, possibly due to lower intravitreal levels of VEgF in response to aflibercept. However, aflibercept was safer than corticosteroids, with no occurrence of elevated intraocular pressure or aggravated cataract observed in the present case series.
there were some limitations of the present study, including a relatively small case number, retrospective and nonrandomized study design, short follow-up period, and results from a single institution. We plan to conduct a large-scale, multicenter, prospective randomized study with 1-to 2-year follow-up in the future, which may provide more details regarding conversion to aflibercept treatment in refractory cases with dME. However, the present study is the first to identify risk factors for poor response to aflibercept in patients with dME refractory to bevacizumab and ranibizumab. in summary, 3 monthly intravitreal aflibercept injections resulted in visual and anatomical improvements in nearly two thirds of participants with dME resistant to bevacizumab or ranibizumab over short-term follow-up. Paradoxical deterioration of visual acuity and macular thickness were detected in poor responders after conversion to continuous 3 monthly aflibercept injections. no differences in age, sex, glycosylated hemoglobin, serum creatinine, total cholesterol, lens status, grades of diabetic retinopathy, or cFt/BcVa values before switching to aflibercept were observed between responders and nonresponders to aflibercept. Previous vitrectomy was found to be the only risk factor associated with poor response to aflibercept treatment. serious systemic and ocular adverse events were not observed in the present case series. 
